Opdivo
nivolumab · PD-1 Immune Checkpoint Inhibitor
Indications & Uses
Advanced melanoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, and MSI-H/dMMR metastatic colorectal cancer.
Contraindications
Severe hypersensitivity to nivolumab or formulation components.
Side Effects & Warnings
Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, cough, and immune-mediated adverse reactions in lungs, colon, liver, and endocrine glands.
Drug & Dietary Interactions
Immunosuppressive therapies may interfere with the pharmacodynamic activity of nivolumab.
Regulatory & Prescribing Information
FDA Approved Biologic (BLA 125554).
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.